-
Jumpcan Partners with Newsoara for PDE4 and Protease Inhibitors in China
•
China-based Jumpcan Pharmaceutical (SHA: 600566) has announced a partnership with compatriot firm Newsoara BioPharma Co., Ltd to develop and commercialize two target products in mainland China. The collaboration involves a PDE4 inhibitor (target product one) and a protease inhibitor (target product two). Jumpcan will pay RMB 180 million (USD 24.8…
